EDIT - Editas Medicine - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

103.2M

Cash

432M

Avg Qtr Burn

-41.19M

Short % of Float

21.96%

Insider Ownership

0.41%

Institutional Own.

67.45%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
EDIT-301 Details Genetic disorder, Beta thalessemia	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EDIT-301 Details Sickle cell disease, Genetic disorder	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EDIT-101 Details Rare diseases, Eye disease , Rare genetic disease, Hepatitis C	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.